Literature DB >> 19153176

The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated.

R A Marrie1, R Horwitz, G Cutter, T Tyry, D Campagnolo, T Vollmer.   

Abstract

BACKGROUND: Mental comorbidity is common in multiple sclerosis (MS), but some studies suggest that mental comorbidity may be underrecognized and undertreated.
OBJECTIVE: Using the North American Research Committee on MS Registry, we assessed the frequency of mental comorbidities in MS and sociodemographic characteristics associated with diagnosis and treatment of depression.
METHODS: We queried participants regarding depression, anxiety, bipolar disorder, and schizophrenia. Depressive symptoms were assessed using the Center for Epidemiologic Studies Depression Scale (CESD); a score>or=21 indicated probable major depression.
RESULTS: Mental comorbidity affected 4264 (48%) responders; depression most frequently (4012, 46%). Among participants not reporting mental comorbidity, 751 (16.2%) had CESD scores>or=21 suggesting undiagnosed depression. Lower socioeconomic status was associated with increased odds of depression (Income $15,000-30,000 vs >$100,000 OR 1.34; 1.11-1.62), undiagnosed depression (Income $15,000-30,000 vs >$100,000 OR 1.52; 1.08-2.13), and untreated depression (<high school vs postgraduate degree OR 3.13; 1.65-5.99).
CONCLUSIONS: Mental comorbidity remains underdiagnosed and undertreated in MS. Patients of lower socioeconomic status bear a disproportionate share of the burden of depression.

Entities:  

Mesh:

Year:  2009        PMID: 19153176     DOI: 10.1177/1352458508099477

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  54 in total

1.  Treatment of mood disorders in multiple sclerosis.

Authors:  Luis Pintor Pérez; Roberto Sánchez González; Eva Baillés Lázaro
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

Review 2.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

3.  Impact of comorbidity on fatigue management intervention outcomes among people with multiple sclerosis: an exploratory investigation.

Authors:  Marcia Finlayson; Katharine Preissner; Chi Cho
Journal:  Int J MS Care       Date:  2013

Review 4.  Multiple sclerosis and sexual dysfunction.

Authors:  Zhen-Ni Guo; Si-Yuan He; Hong-Liang Zhang; Jiang Wu; Yi Yang
Journal:  Asian J Androl       Date:  2012-03-26       Impact factor: 3.285

5.  Cumulative impact of comorbidity on quality of life in MS.

Authors:  R A Marrie; R Horwitz; G Cutter; T Tyry
Journal:  Acta Neurol Scand       Date:  2011-05-26       Impact factor: 3.209

Review 6.  The link between multiple sclerosis and depression.

Authors:  Anthony Feinstein; Sandra Magalhaes; Jean-Francois Richard; Blair Audet; Craig Moore
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

7.  The Prevalence of Bipolar Disorders and Association With Quality of Life in a Cohort of Patients With Multiple Sclerosis.

Authors:  Adalia H Jun-O'Connell; Ankur Butala; Idanis Berrios Morales; Nils Henninger; Kristina M Deligiannidis; Nancy Byatt; Carolina Ionete
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2016-08-19       Impact factor: 2.198

8.  Comorbidities at multiple sclerosis diagnosis.

Authors:  Agnès Fromont; Christine Binquet; Fabien Rollot; Romain Despalins; Alain Weill; Laurence Clerc; Claire Bonithon-Kopp; Thibault Moreau
Journal:  J Neurol       Date:  2013-08-02       Impact factor: 4.849

Review 9.  Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series.

Authors:  Stacey Murray; Andrew Woo
Journal:  Ther Adv Neurol Disord       Date:  2015-12-07       Impact factor: 6.570

10.  Sonographic basal ganglia alterations are related to non-motor symptoms in multiple sclerosis.

Authors:  Sebastian Horowski; Uwe K Zettl; Reiner Benecke; Uwe Walter
Journal:  J Neurol       Date:  2010-08-26       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.